Symbiotec Pharmalab Q2 revenue rises 43% to Rs 280 crore

Symbiotec Pharmalab Limited reported Q2 FY27 revenue of Rs 280 crore, up 43% year on year from Rs 196 crore, while profit after tax rose 169% to Rs 52 crore. The quarter included Rs 53 crore of milestone revenue from a US licensing agreement, an important factor in the reported growth and profitability.

What did Symbiotec Pharmalab report for Q2 FY27?

Symbiotec Pharmalab reported consolidated revenue from operations of Rs 280 crore for the quarter ended Q2 FY27. Revenue was 43% higher than the Rs 196 crore reported in Q2 FY26. The company released its Q2 and H1 FY27 investor presentation on 5 November 2026.

Profit after tax, or PAT, was reported at Rs 52 crore, compared with a lower base in the corresponding quarter a year earlier, resulting in 169% year-on-year growth. The company reported EBITDA of Rs 94 crore, up 88% year on year, while the reported EBITDA margin stood at 32.7%.

The release also showed a substantial improvement in gross margin. Q2 gross margin was 71.6%, compared with 64.1% in Q2 FY26. The investor presentation attributed part of the quarter's operating performance to new businesses and the licensing milestone.

What drove Symbiotec Pharmalab's quarterly revenue growth?

The principal disclosed driver of the reported Q2 increase was a Rs 53 crore milestone revenue receipt linked to a US licensing agreement. The earnings-call summary identified this as a one-time DCV milestone, meaning the reported quarter included an item that may not recur with the same value in subsequent periods.

The company also reported that its core active ingredients business achieved gross margins above 60%. Its presentation referred to new businesses as contributing to the quarterly financial profile, alongside its established operations. However, the available material does not provide a separate revenue break-up for each business vertical.

Management's reported strategy includes expanding DCV injectables and biopharma contract development and manufacturing organisation, or CDMO, services. The company said contracted capacity is expected to begin generating revenue within six to 12 months. That statement concerns expected operational commissioning and does not provide a quantified revenue contribution.

How did Symbiotec Pharmalab perform in the first half of FY27?

Symbiotec Pharmalab reported H1 FY27 revenue of Rs 498 crore, up 25% year on year from Rs 399 crore in H1 FY26. H1 PAT was Rs 66 crore, an increase of 34% from the prior-year period, according to the investor presentation.

The difference between Q2 PAT of Rs 52 crore and H1 PAT of Rs 66 crore indicates that the second quarter accounted for a substantial share of first-half profit. This reflects, among other factors disclosed by the company, the Rs 53 crore milestone revenue recognised during Q2.

Why does the Rs 53 crore milestone matter to investors?

The Rs 53 crore licensing milestone matters because it represented a meaningful part of the Rs 280 crore quarterly revenue figure. It also contributed to the reported increase in EBITDA and PAT. Investors assessing the underlying operating run rate may therefore distinguish recurring product or service revenue from this disclosed one-time item.

The earnings-call summary said revenue and EBITDA were flattered by the milestone. This does not alter the reported results, but it provides context for comparing Q2 with future quarters. The company has not provided quantified details in the supplied material on future licensing milestones, pricing, or the timing of specific capacity revenue.

The quarter also highlights the importance of margins in Symbiotec Pharmalab's business model. Gross margin expansion to 71.6% and a reported EBITDA margin of 32.7% supported profit growth. The company cited a combination of core active ingredients and newer business initiatives in its presentation.

What is Symbiotec Pharmalab planning after the Q2 results?

Symbiotec Pharmalab maintained guidance for about 20% revenue growth and about 25% EBITDA growth for FY27, with a flexibility of plus or minus 5 percentage points. The guidance provides the company's stated framework for the full year, although the supplied material does not give a revised numerical revenue target.

The company has indicated annual capital expenditure of Rs 200 crore to Rs 300 crore. Its investment focus includes DCV injectables and CDMO, where it is seeking to use its industrial-scale fermentation capacity and existing platforms to expand into adjacent offerings.

A recent corporate announcement also recorded confirmation from registrar and share transfer agent MUFG Intime India Private Limited regarding dematerialisation, mutilation and cancellation of security certificates within prescribed timelines. This administrative disclosure is separate from the quarterly operating results.

Conclusion

Symbiotec Pharmalab's Q2 FY27 results showed reported revenue growth of 43% to Rs 280 crore and PAT growth of 169% to Rs 52 crore. Higher gross margin and the Rs 53 crore US licensing milestone supported the quarter, while H1 revenue rose 25% to Rs 498 crore.

Investors will watch delivery against FY27 guidance of about 20% revenue growth and about 25% EBITDA growth, as well as progress on the Rs 200 crore to Rs 300 crore annual capex programme. The timing of revenue from contracted capacity, expected to start within six to 12 months, remains a disclosed operational item to monitor.